In-vitro diagnostics company, Seegene, and Thermo Fisher Scientific have entered a strategic collaboration agreement to combine their products. Seegene will file FDA clearance for its Allplex diagnostic assay portfolio, while Thermo Fisher Scientific will file the same to run Seegene's assays on its QuantStudio 5 Real-Time PCR System (PCR System).
The integrated product will offer a comprehensive MDx solution to the US market.
In a Series C equity financing round, medical-grade wearable biosensor systems developer VitalConnect has raised $33m, which will be used to further commercialise its remote monitoring platform, VitalConnect.
The VitalConnect Platform integrates the data from its VitalPatch biosensor, which is a wearable, adhesive patch that monitors and records eight vital signs of the patient. The device also uses mobile and cloud-based software and analytics, enabling 24/7 remote patient monitoring across care settings.
The financing round has been led by new investors MVM Life Science Partners and Baxter Ventures.
Bonutti Technologies has licensed its two patent families related to knee technologies for use of Zimmer Biomet, a manufacturer of aluminium splints.
Zimmer will use US Patent No 9,301,845 in the development of Persona, a personalised knee system, and NexGen, a complete knee solution.
It has also licensed US Patent Nos 9,269,987 and 9,585,725, which will be used to support the development of Rosa, a robotic total knee application.
In a move to provide high-quality, innovative biologics for use in sports medication procedures, Stryker's Sports Medicine has collaborated with AlloSource, a provider of skin, bone and soft tissue allografts for use in surgical procedures.
Through its nationwide sales force, Stryker will distribute AlloSource biologics for use in a variety of sports medicine procedures.
The collaboration will aid in advancing patient healing and equip many surgeons with biologics collected from tissue donors.
Thermo Fisher Scientific has signed a new agreement with Agios Pharmaceuticals to develop and sell a next-generation sequencing (NGS) oncology companion diagnostic (CDx) for ivosidenib (AG-120) to identify isocitrate dehydrogenase 1 (IDH1) mutations in cholangiocarcinoma, a rare form of cancer affecting the human bile duct system.
Ivosidenib is currently undergoing Phase III clinical trial, in which Thermo Fisher is Agios' technology partner providing NGS for all tumour samples, for the treatment of patients with advanced IDH1m positive cholangiocarcinoma.
Thermo Fisher will be responsible for filing all necessary clearance applications for the test from the regional regulatory agencies and will also have the rights to commercialise the test globally.